NO308533B1 - Heteroarylaminer, anvendelse derav og farmasøytisk preparat - Google Patents

Heteroarylaminer, anvendelse derav og farmasøytisk preparat

Info

Publication number
NO308533B1
NO308533B1 NO941179A NO941179A NO308533B1 NO 308533 B1 NO308533 B1 NO 308533B1 NO 941179 A NO941179 A NO 941179A NO 941179 A NO941179 A NO 941179A NO 308533 B1 NO308533 B1 NO 308533B1
Authority
NO
Norway
Prior art keywords
heteroarlamines
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
NO941179A
Other languages
English (en)
Norwegian (no)
Other versions
NO941179D0 (no
NO941179L (no
Inventor
Yuhpyng Liang Chen
Arthur Adam Nagel
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO941179D0 publication Critical patent/NO941179D0/no
Publication of NO941179L publication Critical patent/NO941179L/no
Publication of NO308533B1 publication Critical patent/NO308533B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Control Of El Displays (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO941179A 1991-10-03 1994-03-30 Heteroarylaminer, anvendelse derav og farmasøytisk preparat NO308533B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77128391A 1991-10-03 1991-10-03
PCT/US1992/007230 WO1993007140A1 (en) 1991-10-03 1992-08-31 Heteroaryl amines as novel acetyl cholinesterase inhibitors

Publications (3)

Publication Number Publication Date
NO941179D0 NO941179D0 (no) 1994-03-30
NO941179L NO941179L (no) 1994-03-30
NO308533B1 true NO308533B1 (no) 2000-09-25

Family

ID=25091318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941179A NO308533B1 (no) 1991-10-03 1994-03-30 Heteroarylaminer, anvendelse derav og farmasøytisk preparat

Country Status (36)

Country Link
US (4) US5574046A (enExample)
EP (1) EP0606248B1 (enExample)
JP (1) JP2546785B2 (enExample)
KR (1) KR0170458B1 (enExample)
CN (1) CN1035615C (enExample)
AP (1) AP314A (enExample)
AT (1) ATE235490T1 (enExample)
AU (1) AU667053B2 (enExample)
BG (1) BG61727B1 (enExample)
BR (1) BR9206577A (enExample)
CA (1) CA2119647C (enExample)
CZ (1) CZ290807B6 (enExample)
DE (2) DE9290112U1 (enExample)
DK (1) DK0606248T3 (enExample)
EG (1) EG21481A (enExample)
ES (1) ES2193137T3 (enExample)
FI (1) FI116939B (enExample)
HU (1) HU225049B1 (enExample)
IL (1) IL103274A (enExample)
IS (1) IS1745B (enExample)
MA (1) MA22672A1 (enExample)
MX (1) MX9205678A (enExample)
NO (1) NO308533B1 (enExample)
NZ (1) NZ244601A (enExample)
OA (1) OA09895A (enExample)
PH (1) PH31290A (enExample)
PL (3) PL171693B1 (enExample)
PT (1) PT100917B (enExample)
RO (1) RO112868B1 (enExample)
RU (1) RU2100357C1 (enExample)
SG (1) SG52618A1 (enExample)
TW (1) TW263504B (enExample)
UA (1) UA41290C2 (enExample)
UY (1) UY23484A1 (enExample)
WO (1) WO1993007140A1 (enExample)
ZA (1) ZA927589B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EP1118322A4 (en) 1998-09-30 2004-10-20 Takeda Chemical Industries Ltd MEDICINES THAT IMPROVE BLADDER DRAINING POWER
SE9902268D0 (sv) * 1999-06-16 1999-06-16 Astra Ab Pharmaceutically active compounds
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
IL154685A0 (en) * 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びhcv阻害剤としてのその使用
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
EP1753764B1 (en) 2004-06-09 2008-10-29 Glaxo Group Limited Pyrrolopyridine derivatives
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
CN1808106B (zh) * 2005-01-21 2010-11-24 中国科学院上海药物研究所 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法
ES2463766T3 (es) * 2008-08-12 2014-05-29 Zinfandel Pharmaceuticals, Inc. Método de identificación de factores de riesgo de la enfermedad de Alzheimer
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
KR20190082985A (ko) 2009-10-02 2019-07-10 아벡신 에이에스 소염제 2-옥소티아졸 및 2-옥소옥사졸
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2012096873A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2014211489A1 (en) 2013-01-29 2015-08-13 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN107141266B (zh) * 2017-06-28 2019-04-09 佳木斯大学附属第一医院 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL100127C (enExample) * 1954-04-28
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4122265A (en) * 1976-05-21 1978-10-24 Hoffmann-La Roche Inc. Derivatives of 3-phenylisoindole-1-carboxylic acid
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
US5064840A (en) * 1989-08-03 1991-11-12 Merrell Dow Pharmaceuticals Anti-psychotic piperidylbenzimidazole compounds
TW197442B (enExample) * 1990-02-08 1993-01-01 Pfizer
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
TW197435B (enExample) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
FI943727A0 (fi) * 1992-02-13 1994-08-12 Merrell Dow Pharma Piperidinyylitiasyklisiä johdannaisia
TW226019B (enExample) * 1992-03-23 1994-07-01 Sankyo Co

Also Published As

Publication number Publication date
JP2546785B2 (ja) 1996-10-23
KR0170458B1 (ko) 1999-02-18
CN1071166A (zh) 1993-04-21
PL171669B1 (en) 1997-06-30
US6124321A (en) 2000-09-26
CA2119647C (en) 1998-08-04
RO112868B1 (ro) 1998-01-30
DE9290112U1 (de) 1994-06-01
RU2100357C1 (ru) 1997-12-27
UY23484A1 (es) 1993-03-11
CA2119647A1 (en) 1993-04-15
US5574046A (en) 1996-11-12
PH31290A (en) 1998-07-06
PL171693B1 (pl) 1997-06-30
FI941518L (fi) 1994-03-31
PT100917A (pt) 1993-11-30
EG21481A (en) 2001-11-28
ES2193137T3 (es) 2003-11-01
HUT70544A (en) 1995-10-30
ATE235490T1 (de) 2003-04-15
IL103274A (en) 1996-11-14
AU2519692A (en) 1993-05-03
BG98689A (bg) 1995-03-31
CZ78594A3 (en) 1995-07-12
NZ244601A (en) 1995-03-28
BR9206577A (pt) 1995-10-10
BG61727B1 (bg) 1998-04-30
AP314A (en) 1994-02-04
DK0606248T3 (da) 2003-06-23
OA09895A (en) 1995-09-15
PT100917B (pt) 1999-07-30
EP0606248B1 (en) 2003-03-26
AU667053B2 (en) 1996-03-07
IL103274A0 (en) 1993-02-21
AP9200421A0 (en) 1992-10-31
CN1035615C (zh) 1997-08-13
IS1745B (is) 2000-05-18
UA41290C2 (uk) 2001-09-17
ZA927589B (en) 1994-04-05
HU9400952D0 (en) 1994-06-28
MX9205678A (es) 1993-04-01
NO941179D0 (no) 1994-03-30
CZ290807B6 (cs) 2002-10-16
JPH06510788A (ja) 1994-12-01
FI941518A0 (fi) 1994-03-31
EP0606248A1 (en) 1994-07-20
DE69232976T2 (de) 2003-10-02
US20020049210A1 (en) 2002-04-25
FI116939B (fi) 2006-04-13
PL171984B1 (pl) 1997-07-31
DE69232976D1 (de) 2003-04-30
NO941179L (no) 1994-03-30
US6303633B1 (en) 2001-10-16
MA22672A1 (fr) 1993-07-01
SG52618A1 (en) 1998-09-28
TW263504B (enExample) 1995-11-21
HU225049B1 (en) 2006-05-29
WO1993007140A1 (en) 1993-04-15
IS3919A (is) 1993-04-04

Similar Documents

Publication Publication Date Title
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
DK1023900T3 (da) Farmaceutisk præparat indeholdende S-nitroso-lipoproteiner og anvendelse deraf
NO924768L (no) Farmasoeytisk preparat og fremgangsmaate for dets fremstilling
NO921958L (no) Farmasoeytisk preparat
NO922006D0 (no) Farmasoeytisk preparat
FI923582L (fi) Farmaceutisk sferoidkomposition
IS3720A7 (is) Afleiður dialkoxy-pyridinyl-benzimidazole, aðferðvið lögun þeirra og lyfjafræðileg notkun
FI922958L (fi) Farmaceutisk sammansaettning
NO306398B1 (no) Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO303446B1 (no) Nye 2-sakkarinylmetylaryl- og -aryloksyacetater, preparater og anvendelse derav
MX9200622A (es) Composicion farmaceutica
FI934680A7 (fi) Aryylimorfoliini, valmistus ja käyttö
NO303637B1 (no) 7-disubstituert-metyl-4-okso-3H,5H-pyrrolo-£3,2-d|pyrimidin, farmas°ytisk preparat, og anvendelse derav
ITMI911470A1 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
ITMI912261A0 (it) Composizioni farmaceutiche contenenti clozapina, loro preparazione e loro impiego
DK73091D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
NO923536D0 (no) Substituert aminopropan, fremgangsmaate for fremstilling og anvendelse
NO922992D0 (no) Imid-terminerte polynitrogenforbindelser, deres fremstilling og anvendelse
KR930701587A (ko) 사람 로타바이러스 hcr3, 그것의 재조립체 및 그것을 포함하는 백신 조성물
NO911298D0 (no) Farmasoeytisk preparat og anvendelse derav.
NO921049L (no) Bakterieinhiberende preparat og anvendelse derav
BR1100486A (pt) Composto e composição farmacêutica